How to Administer Norepinephrine Continuous Intravenous Infusion
Norepinephrine must be diluted in 5% dextrose solution (not saline alone) and administered through a large central vein at an initial rate of 8-12 mcg/min (2-3 mL/min of standard dilution), then titrated to maintain mean arterial pressure ≥65 mmHg, with typical maintenance doses of 2-4 mcg/min. 1
Preparation and Dilution
Standard concentration: Add 4 mg (4 mL) of norepinephrine to 1,000 mL of 5% dextrose injection or 5% dextrose with sodium chloride to yield 4 mcg/mL 1. Dextrose-containing solutions are essential as they protect against oxidation and loss of potency—administration in saline solution alone is not recommended 1.
For situations requiring fluid restriction, more concentrated solutions may be used. Conversely, if large fluid volumes are needed, use a more dilute concentration to avoid excessive vasopressor dosing per unit time 1.
Route of Administration
Central venous access is strongly preferred. Insert a plastic intravenous catheter through a suitable bore needle well advanced centrally into a large vein, secured with adhesive tape 1. Avoid catheter tie-in techniques as they promote stasis 1.
Peripheral administration: Recent evidence suggests that lower concentrations (≤5 mcg/mL) may be safely administered peripherally in select patients, though this remains off-label and requires close monitoring for extravasation 2. In one pilot study of 87 patients receiving peripheral norepinephrine, only 3% experienced adverse events, none serious 2.
Initial Dosing
Start with 8-12 mcg/min (2-3 mL/min of standard 4 mcg/mL dilution) and observe the response 1. An IV drip chamber or infusion pump is essential for accurate flow rate measurement 1.
The target is to establish and maintain systolic blood pressure of 80-100 mmHg, sufficient to maintain circulation to vital organs 1. For previously hypertensive patients, raise blood pressure no higher than 40 mmHg below their pre-existing systolic pressure 1.
Titration and Maintenance
Average maintenance dose: 2-4 mcg/min (0.5-1 mL/min) 1. However, great individual variation exists—titrate according to patient response 1.
For septic shock specifically, the 2016 Surviving Sepsis Campaign guidelines recommend targeting a mean arterial pressure (MAP) of 65 mmHg initially 3. One multicenter trial found no mortality benefit from targeting MAP of 85 mmHg versus 65 mmHg, though the higher target increased arrhythmia risk 3. The exception is patients with chronic hypertension, who had reduced need for renal replacement therapy at the higher MAP target 3.
High-dose scenarios: Occasionally, much larger doses (up to 68 mg base daily, or approximately 47 mcg/min) may be necessary if hypotension persists 1. However, when high doses are required, always suspect and correct occult blood volume depletion first 1. Central venous pressure monitoring is helpful for detecting this 1.
Critical Prerequisite: Volume Resuscitation
Blood volume depletion must be corrected as fully as possible before administering any vasopressor 1. The only exception is when intraaortic pressures must be maintained emergently to prevent cerebral or coronary ischemia—in this case, norepinephrine can be given concurrently with volume replacement 1.
For acute hypotensive states, administer 1-2 L of normal saline to adults at 5-10 mL/kg in the first 5 minutes 4. Children should receive up to 30 mL/kg in the first hour 4.
Monitoring Parameters
Essential monitoring includes:
- Blood pressure every 1-5 minutes initially, then as clinically indicated
- Heart rate continuously (watch for bradycardia or tachyarrhythmias)
- Urine output (target >0.5 mL/kg/hr)
- Peripheral perfusion (skin temperature, color, capillary refill)
- Continuous ECG monitoring for arrhythmias 1
When hemodynamic monitoring is available (emergency department or ICU), continuous monitoring is essential 4. Even without advanced monitoring, check blood pressure and pulse every minute and perform ECG monitoring if available 4.
Duration and Discontinuation
Continue the infusion until adequate blood pressure and tissue perfusion are maintained without therapy 1. Reduce gradually—avoid abrupt withdrawal 1. In some cases of vascular collapse from acute myocardial infarction, treatment may be required for up to 6 days 1.
Critical Safety Considerations
Extravasation risk: Infiltration can cause severe skin injury 5. If extravasation occurs, inject phentolamine 0.1-0.2 mg/kg (up to 10 mg) diluted in 10 mL of 0.9% sodium chloride intradermally at the site to counteract dermal vasoconstriction 5.
Drug incompatibilities: Avoid contact with iron salts, alkalis, or oxidizing agents 1. Do not use if the solution is pinkish, darker than slightly yellow, or contains precipitate 1.
Arrhythmia risk: Norepinephrine may cause tachyarrhythmias, ectopic beats, and potentially lethal arrhythmias, particularly at higher doses 5. This risk necessitates continuous cardiac monitoring.
Renal and splanchnic effects: Infusion rates >20 mcg/kg/min may cause peripheral, renal, and splanchnic vasoconstriction and ischemia 5. Recent data from cardiogenic shock patients showed that higher norepinephrine doses were independently associated with acute kidney injury (OR 1.001 per µg/kg; p=0.042) 6.
Alternative Vasopressors
If hypotension remains refractory to norepinephrine and volume replacement, consider adding vasopressin or switching to dopamine 2-20 mcg/kg/min 4. For patients on beta-blockers, consider glucagon 1-5 mg IV over 5 minutes followed by infusion of 5-15 mcg/min 4.